Most people can relate to discomfort from heartburn and regurgitation, two of the most common symptoms caused by GERD. Symptoms often occur during or after eating and drinking, which affects both motivation and the ability to enjoy social activities such as picnics, dinners, events, or just a cup of coffee with friends. More severe stages of GERD with the presence of esophageal erosions (eGERD) or ulcerations (complicated GERD) can be very painful.
Clinical Stage Pharma
Developing small molecules for the treatment of gastric acid related diseases.
The Next Leap Forward
Blockbuster Proton Pump Inhibitors (PPIs) such as Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. The time has now come for Potassium-Competitive Acid Blockers (P-CABs) to take the next leap forward in the treatment of acid-related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate takes a new approach to provide improved management of GERD and for the treatment of Helicobacter Pylori (H.Pylori) infection.
![Cinclus Pharma man with GERD startpage](/media/ql5d1wl2/cinclus-image-gerd-start-2044x1500.jpg?rmode=max&width=1270&v=1d9571e8a5b87b0)
![cinclus pharma illustration of linazapran molecule grey](/media/d1ilh50i/molekyl-gra.png?rmode=max&width=1270&v=1d82893e456d8b0)
Linaprazan glurate
Built on world-leading industrial tradition, linaprazan glurate is a gastric acid blocker and therapy with great potential for healing GERD. Several clinical Phase I trials have been successfully completed and in 2022 the clinical Phase II trial was completed. Linaprazan glurate represents an improved mode of action with the potential for superior clinical efficacy and beneficial pharmacokinetic profile compared to PPIs.
Latest News
![cinclus pharma male doctor consulting woman](/media/mfhl52ed/cinclus-image-medical-2044x1200-02.jpg?width=620&height=400&v=1d8288f4fd122d0)
Read the full analysis of Cinclus Pharma in the article by Börsveckan.
Here you can read the full analysis of Cinclus Pharma in the article by Börsveckan.
![Cinclus News Image Christer Trill 01](/media/eg3nxayq/cinclus-news-image-christer-trill-01.jpg?width=620&height=400&v=1dad43fbc49c3f0)
Interview with CEO of Cinclus Pharma, Christer Ahlberg, after the listing.
Interview with CEO of Cinclus Pharma, Christer Ahlberg, after the listing.
![Cinclus News Image Christer Trill 02 (1)](/media/45gpznzt/cinclus-news-image-christer-trill-02.jpg?width=620&height=400&v=1da26c187521ca0)
Interview with Christer Ahlberg, CEO of Cinclus Pharma, in Börspodden
CEO of Cinclus Pharma, Christer Ahlberg, has participated in Börspodden to talk about the listing that took place last week and the upcoming plans for the company.
![cinclus pharma bistro with greenery in the ceiling](/media/kaldmrvp/cinclus-product-image-2044x1200-02.jpg?rxy=0.89599670246935914,0.46390364683088231&width=635&height=335&v=1d828901f3888b0)
CHRISTER AHLBERG
CEO CINCLUS PHARMA